Answers are grounded in this paper and cite their sources.
We studied the predictive value of self-reported adherence and plasma drug concentrations on virological rebound to HAART. Among 238 participants in the AdICoNA study who had viral load < or = 500 copies/ml, 42 (17.6%) experienced virological rebound by 96 weeks. Both self-reported non-adherence and sub-optimal concentration were independently associated with a higher risk of virological rebound.
No takes yet. Share an insight, caveat, or question.
Antinori et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: